Advertisement


Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Luis I. Ruffolo, MD, of the University of Rochester, discusses preclinical studies showing that semaphorin 4D blockade may sensitize pancreatic tumors to chemoimmunotherapy combinations (Abstract 26).



Related Videos

Immunotherapy
Symptom Management
Skin Cancer

Kevin Tyan on Colitis Induced by Immune Checkpoint Inhibitors: Potential Preventive Strategy

Kevin Tyan, of Kinnos, and currently a medical school student at Harvard University, discusses his study findings, which showed that patients with melanoma who are treated with immunotherapy had a significantly lower risk of developing colitis if they also took vitamin D ( Abstract 89).

Martin McCarter, MD, on Refinement of Surgical Treatment: Expert Perspective on ASCO’s 2020 Advance of the Year

Martin McCarter, MD, of the University of Colorado Denver, discusses the recent strides in surgical oncology, how the role of surgery has changed, and what lies ahead for this staple of cancer therapy.

Skin Cancer
Breast Cancer
Lung Cancer

Elizabeth A. Mittendorf, MD, PhD, on Mobilizing the Immune System to Treat Select Solid Tumors

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, summarizes a session she co-chaired on utilizing the immune system in neoadjuvant trials to treat melanoma, breast, and lung cancers.

Lung Cancer

Jarrett Failing, MD, on Human Leukocyte Antigen Expression in NSCLC With Brain Metastases

Jarrett Failing, MD, of the Mayo Clinic, discusses his study data, which show some agreement between the expression of human leukocyte antigens in primary non–small cell lung cancer with brain metastasis. His findings may have some bearing on resistance to immune checkpoint inhibitors (Abstract 43).

Immunotherapy

Dario Vignali, PhD, on Immune Resistance Mechanisms in Cancer

Dario Vignali, PhD, of the University of Pittsburgh and UPMC Hillman Cancer Center, summarizes his Keynote Address, which covered what drives systemic immune dysfunction in patients with cancer, what promotes inhibitory receptor expression, and what limits the persistence of antigen-specific T cells.

Advertisement

Advertisement



Advertisement